Fifty percent of ocular myasthenia gravis (OMG) patients will progress to generalized myasthenia, 90% within 3 years from the onset of ocular symptoms. This study was performed to determine whether treatment with oral prednisone initiated and completed within 2 years from the onset of ocular symptoms would affect the progression of ocular myasthenia to generalized myasthenia gravis (GMG). Fifty-six patients were included in this review, with 27 patients in the prednisone-treated group and 29 patients in the untreated group. The treated group was initiated on 60 mg of prednisone daily with a slow taper over 3–6 months. At 2 years, significantly fewer patients in the treated group (3 of 27) progressed to generalized myasthenia when compared to the untreated group (10 of 29) (χ2, p=0.04). Our results suggest that the early use of steroids may decrease progression of ocular to generalized myasthenia gravis. The decision to use steroids should be considered early in the course of patients diagnosed with ocular myasthenia gravis. This study should be considered preliminary and a prospective trial is warranted to confirm our observations.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of the Neurological Sciences
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Prognosis of ocular myasthenia.Ann. Neurol. 1983; 14: 516-519
- Ocular manifestations of myasthenia gravis.Arch. Ophthalmol. 1941; 26: 969-982
- Ocular myasthenia gravis.Invest. Ophthalmol. 1958; 6: 277-287
- Ocular myasthenia gravis: a protean disorder.Surv. Ophthalmol. 1994; 39: 169-210
- The course of myasthenia gravis and therapies affecting outcome.Ann. N.Y. Acad. Sci. 1987; 505: 472-499
- Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England.J. Neurol. Neurosurg. Psychiatry. 1998; 65: 492-496
- Ocular myasthenia gravis; a critical review of clinical and pathophysiological aspects.Doc. Ophthalmol. 1993; 84: 309-333
- Ocular myasthenia gravis: response to long term immunosuppressive treatment.J. Neurol. Neurosurg. Psychiatry. 1997; 62: 156-162
- The ocular signs and symptoms of myasthenia gravis.Doc. Ophthalmol. 1982; 52: 363-378
- Ocular myasthenia gravis: predictive value of single-fiber electromyography.Muscle Nerve. 1999; 22: 1222-1227
- Myasthenia gravis.N. Engl. J. Med. 1994; 330: 1797-1810
- Beneficial effects of prednisone on ocular myasthenia gravis.Arch. Neurol. 1996; 53: 802-804
- Development of generalized disease at 2 years in patients with ocular myasthenia gravis.Arch. Neurol. 2003; 60: 243-248
- Treatment of ocular myasthenia with prednisone.Arch. Neurol. 2000; 57: 750-753
Accepted: August 25, 2003
Received in revised form: August 21, 2003
Received: March 24, 2003
© 2003 Elsevier B.V. Published by Elsevier Inc. All rights reserved.